Physician profile
Kyle D James
NPI 1497745426
$3,021.58
in general payments reported to CMS, 2019-2025
36 companies · $676 in 2025
The $676 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $274 · 2021: $304 · 2022: $421 · 2023: $460 · 2024: $427 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.41 | 2021-2025 | |
| Pfizer INC. | $208.66 | 2019-2025 | |
| Novo Nordisk INC | $166.94 | 2019-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.14 | 2019-2023 | |
| Glaxosmithkline, LLC. | $159.32 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $158.15 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $144.99 | 2019-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $144.38 | 2019-2023 | Myrbetriq |
| Dexcom, INC. | $127.34 | 2021-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $108.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $99.56 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $73.40 | 2019-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $73.35 | 2020-2025 | Zoryve, Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $59.48 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $50.45 | 2023-2024 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $48.55 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $45.03 | 2020-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $42.02 | 2025 | Gemtesa |
| Abbott Laboratories | $38.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.55 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $32.36 | 2022 | |
| Radius Health, INC. | $30.31 | 2019 | |
| Edwards Lifesciences Corporation | $27.84 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.36 | 2019-2020 | |
| Amgen INC. | $25.70 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.22 | 2022 | |
| Exact Sciences Corporation | $19.71 | 2025 | The Cologuard Plus Collection Kit |
| Bausch Health US, LLC | $16.45 | 2019 | |
| Eisai INC. | $15.62 | 2020 | |
| Amarin Pharma, INC. | $14.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2024 | Xifaxan |
| Ironshore Pharmaceuticals INC. | $14.14 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.90 | 2024 | Voquezna |
| Antares Pharma, INC. | $13.64 | 2019 | |
| Tris Pharma INC | $13.07 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.